Download
1-s2.0-S1877282X09000629-main.pdf 268,77KB
WeightNameValue
1000 Titel
  • Challenges and potential solutions to innovative vaccine development for developing countries
1000 Autor/in
  1. Milstien, Julie |
1000 Erscheinungsjahr 2009
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2009-08-24
1000 Erschienen in
1000 Quellenangabe
  • 1(1):183-188
1000 Copyrightjahr
  • 2009
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1016/j.provac.2009.07.031 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • INTRODUCTION:. One of the barriers to meeting Millennium Development Goal Number 4 is access for large populations of developing countries to vaccines against their most serious and common diseases. Innovative vaccines have been more readily available at affordable prices once more producers enter the market, but this means that there will be a delay in access until these manufacturers can access the technology. Several solutions to enhance access have been proposed; none so far is optimal. METHODS: The factors relating to competition in the market and an affordable price were examined. Historical price data to countries were reviewed. Various explanations for lack of competition were also analyzed, including unequal access to financing, lack of optimal research and development capacity, barriers to technology transfer, issues in accessibility to intellectual property. RESULTS: Differences in vaccine scale up, know-how, GMP practices and regulatory oversight are decreasing between emerging suppliers and established multinationals. Developing country vaccine prices are at about the same levels for all manufacturers, but the level of vaccine development is lower for emerging suppliers who have few high priced markets to offset investments. There appear to be three major differences between multinational manufacturers and emerging suppliers: (1) limited access to research results that lead to new vaccine constructs; (2) barriers to vaccine technology development relating to blocking intellectual property; (3) inability to spread the investments that would be incurred in addressing issues (1) and (2) over a large enough financial base. In terms of pricing, experience with early adopting countries has shown that other factors may overcome the perceived pricing barrier: that is, willingness to pay appears not to correlate with country wealth. CONCLUSION: Based on these analyses it appears that the interventions of the international community might be better directed to achieve vaccine access.
1000 Sacherschließung
lokal vaccine development
lokal willingness to pay
lokal innovation
lokal vaccine access
lokal vaccine pricing
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TWlsc3RpZW4sIEp1bGll
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6429831.rdf
1000 Erstellt am 2021-10-14T12:15:51.101+0200
1000 Erstellt von 218
1000 beschreibt frl:6429831
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2021-11-02T13:28:04.899+0100
1000 Objekt bearb. Tue Oct 26 11:40:26 CEST 2021
1000 Vgl. frl:6429831
1000 Oai Id
  1. oai:frl.publisso.de:frl:6429831 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source